Erythropoietin in traumatic brain injury: Study protocol for a randomised controlled trial

Trials

Volumn 16, Issue 1, 2015, Pages

  Nichol, Alistair ^a,b,c,d   French, Craig ^e,f   Little, Lorraine ^a   Presneill, Jeffrey ^a,g   Cooper, D James ^a,b   Haddad, Samir ^a,h   Duranteau, Jacques ^a,i   Huet, Olivier ^j   Skrifvars, Markus ^k   Arabi, Yaseen ^a,l   Bellomo, Rinaldo ^a,f,m  

^a MONASH UNIVERSITY   (Australia)

^b The Alfred ^*  (Australia)

^c ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^d UNIVERSITY COLLEGE DUBLIN   (Ireland)

^e WESTERN HEALTH   (Australia)

^f UNIVERSITY OF MELBOURNE   (Australia)

^g MATER HOSPITAL   (Australia)

^h KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

ⁱ BICÊTRE HOSPITAL   (France)

^j UNIVERSITÉ DE BRETAGNE OCCIDENTALE   (France)

^k HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^l KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

^m AUSTIN HEALTH   (Australia)

more..

Author keywords

Critical care; Erythropoietin; Outcome; Randomised controlled trials; Traumatic brain injury

Indexed keywords

HEMOGLOBIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; ERYTHROPOIETIN;

ACUTE HEART INFARCTION; AGED; ARTICLE; AUSTRALIA; CEREBROVASCULAR ACCIDENT; CLINICAL PROTOCOL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CRITICALLY ILL PATIENT; DEEP VEIN THROMBOSIS; DOPPLER FLOWMETRY; DRUG COST; DRUG EFFICACY; DRUG SAFETY; FEMALE; FINLAND; FOLLOW UP; FRANCE; GERMANY; GLASGOW OUTCOME SCALE; HEART ARREST; HEART VENTRICLE FIBRILLATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; INJURY SEVERITY; INTENSIVE CARE UNIT; INTENTION TO TREAT ANALYSIS; IRELAND; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEW ZEALAND; PHASE 3 CLINICAL TRIAL; PROSPECTIVE STUDY; QUALITY OF LIFE; QUALITY OF LIFE ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SAUDI ARABIA; SHORT FORM 12; THROMBOEMBOLISM; TRAUMATIC BRAIN INJURY; TREATMENT DURATION; TREATMENT OUTCOME; ADOLESCENT; ADULT; BRAIN INJURIES; CLINICAL TRIAL; DOPPLER ULTRASONOGRAPHY; MIDDLE AGED; OUTCOME ASSESSMENT; SAMPLE SIZE; STATISTICAL ANALYSIS;

ADOLESCENT; ADULT; AGED; BRAIN INJURIES; CLINICAL PROTOCOLS; DATA INTERPRETATION, STATISTICAL; ERYTHROPOIETIN; HUMANS; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); SAMPLE SIZE; THROMBOEMBOLISM; ULTRASONOGRAPHY, DOPPLER;

EID: 84924258538     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/s13063-014-0528-6     Document Type: Article

References (34)

1. Access Economics. The economic cost of spinal cord injury and traumatic brain injury in Australia. Report by Access Economics Pty Limited for The Victorian Neurotrauma Initiative. 2009; last access date 28 Jan 2015. http://www.tac.vic.gov.au/about-the-tac/our-organisation/research/tac-neurotrauma-research/vni/the20economic20cost20of20spinal20cord20injury20and20traumatic20brain20injury20in20australia.pdf
2. Bramlett HM, Dietrich WD. Pathophysiology of cerebral ischemia and brain trauma: similarities and differences. J Cereb Blood Flow Metab. 2004;24:133-50.
3. Lykissas MG, Korompilias AV, Vekris MD, Mitsionis GI, Sakellariou E, Beris AE. The role of erythropoietin in central and peripheral nerve injury. Clin Neurol Neurosurg. 2007;109:639-44.
4. Coleman T, Brines M. Science review: recombinant human erythropoietin in critical illness: a role beyond anemia? Crit Care. 2004;8:337-41.
5. Yatsiv I, Grigoriadis N, Simeonidou C, Stahel PF, Schmidt OI, Alexandrovitch AG, et al. Erythropoietin is neuroprotective, improves functional recovery, and reduces neuronal apoptosis and inflammation in a rodent model of experimental closed head injury. FASEB J. 2005;19:1701-3.
6. Lu D, Mahmood A, Qu C, Goussev A, Schallert T, Chopp M. Erythropoietin enhances neurogenesis and restores spatial memory in rats after traumatic brain injury. J Neurotrauma. 2005;22:1011-7.
7. Corwin HL, Gettinger A, Pearl RG, Fink MP, Levy MM, Shapiro MJ, et al. Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial. JAMA. 2002;288:2827-35.
8. Corwin HL, Gettinger A, Fabian TC, May A, Pearl RG, Heard S, et al. Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med. 2007;357:965-76.
9. Abrishamkar S, Safavi M, Honarmand A. Effect of erythropoietin on Glasgow Coma Scale and Glasgow Outcome Sale in patient with diffuse axonal injury. J Res Med Sci. 2012;17:51-6.
10. Talving P, Lustenberger T, Inaba K, Lam L, Mohseni S, Chan L, et al. Erythropoiesis-stimulating agent administration and survival after severe traumatic brain injury: a prospective study. Arch Surg. 2012;147:251-5.
11. Tonia T, Mettler A, Robert N, Schwarzer G, Seidenfeld J, Weingart O, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev. 2012;12:CD003407.
12. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085-98.
13. Teasdale GM, Pettigrew LE, Wilson JT, Murray G, Jennett B. Analyzing outcome of treatment of severe head injury: a review and update on advancing the use of the Glasgow Outcome Scale. J Neurotrauma. 1998;15:587-97.
14. Ware Jr J, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34:220-33.
15. EuroQol Group. EQ-5D™ instrument for describing and valuing health-related quality of life. 2014. Last access date 28 Jan 2015. http://www.euroqol.org/home.html.
16. Cook DJ, Rocker G, Meade M, Guyatt G, Geerts W, Anderson D, et al. Prophylaxis of Thromboembolism in Critical Care (PROTECT) Trial: a pilot study. J Crit Care. 2005;20:364-72.
17. Vincent JL, Baron JF, Reinhart K, Gattinoni L, Thijs L, Webb A, et al. Anemia and blood transfusion in critically ill patients. JAMA. 2002;288:1499-507.
18. Corwin HL, Gettinger A, Pearl RG, Fink MP, Levy MM, Abraham E, et al. The CRIT Study: anemia and blood transfusion in the critically ill - current clinical practice in the United States. Crit Care Med. 2004;32:39-52.
19. Brain Trauma Foundation. Guidelines for the management of severe traumatic brain injury. J Neurotrauma. 2007;24 Suppl 1:S1-106.
20. Marshall LF, Marshall SB, Klauber MR, Van Berkum CM, Eisenberg H, Jane JA, et al. The diagnosis of head injury requires a classification based on computed axial tomography. J Neurotrauma. 1992;9 Suppl 1:S287-92.
21. Wilson JT, Pettigrew LE, Teasdale GM. Structured interviews for the Glasgow Outcome Scale and the extended Glasgow Outcome Scale: guidelines for their use. J Neurotrauma. 1998;15:573-85.
22. Fergusson D, Aaron SD, Guyatt G, Hebert P. Post-randomisation exclusions: the intention to treat principle and excluding patients from analysis. BMJ. 2002;325:652-4.
23. Perner A, Haase N, Guttormsen AB, Tenhunen J, Klemenzson G, Aneman A, et al. Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis. N Engl J Med. 2012;367:124-34.
24. Dijkers MP. Quality of life after traumatic brain injury: a review of research approaches and findings. Arch Phys Med Rehabil. 2004;85:S21-35.
25. Bullinger M, Azouvi P, Brooks N, Basso A, Christensen AL, Gobiet W, et al. Quality of life in patients with traumatic brain injury-basic issues, assessment and recommendations. Restor Neurol Neurosci. 2002;20:111-24.
26. Myburgh JA, Cooper DJ, Finfer SR, Venkatesh B, Jones D, Higgins A, et al. Epidemiology and 12-month outcomes from traumatic brain injury in Australia and New Zealand. J Trauma. 2008;64:854-62.
27. Myburgh J, Cooper DJ, Finfer S, Bellomo R, Norton R, Bishop N, et al. Saline or albumin for fluid resuscitation in patients with traumatic brain injury. N Engl J Med. 2007;357:874-84.
28. Hosmer DW, Lemeshow S, Sturdivant RX. Applied logistic regression. Hoboken, New Jersey: Wiley; 2013.
29. Roozenbeek B, Lingsma HF, Perel P, Edwards P, Roberts I, Murray GD, et al. The added value of ordinal analysis in clinical trials: an example in traumatic brain injury. Crit Care. 2011;15:R127.
30. Cummings P. Re: converting an adjusted odds ratio to a risk ratio will produce biased estimates. BMJ. 2014; 348:f7450/rr/684808.
31. Grant RL. Converting an odds ratio to a range of plausible relative risks for better communication of research findings. BMJ. 2014;348:f7450.
32. Norton EC, Miller MM, Kleinman LC. Computing adjusted risk ratios and risk differences in Stata. Stata J. 2013;13:492-509.
33. Jennison C, Turnbull BW. Group sequential methods with applications to clinical trials. Boca Raton, Florida: Chapman & Hall/CRC; 2000.
34. Cook D, Lauzier F, Rocha MG, Sayles MJ, Finfer S. Serious adverse events in academic critical care research. CMAJ. 2008;178:1181-4.